A preclinical study examined the synergistic effects of JQ1 (BRD4 inhibitor) and Alisertib (AURKA inhibitor) in MYCN-amplified neuroblastoma cell lines and mouse models (108). This evidence concerns the gene MYCN and neuroblastoma.